 |
| The Optune system--Courtesy of Novocure |
St. Helier, NJ's Novocure ($NVCR) submitted a PMA supplement with the FDA, in hopes of marketing an upgraded version of its noninvasive Optune system to treat glioblastoma, a type of brain tumor. PMA supplements enable modifications to PMA-approved devices. The second generation Optune system weighs 2.7 pounds, compared to 6 pounds for the current version. "The big improvement with the second generation device is the reduction in size and weight achieved by digital signal generation technology. From a patient-convenience view, we believe it is a significant step forward," said Novocure COO Mike Ambrogi, in a statement. The second-generation of the Optune is already available in Europe. Release
@FierceMedDev: Clearside announces positive Phase II results in win for back-of-the-eye drug delivery. FierceDrugDelivery story | Follow @FierceMedDev
@EmilyWFierce: This question has been on my mind for a while. What does the "F" in F. Michael Ball stand for? More | Follow @EmilyWFierce
@VarunSaxena2: Medtronic CEO ambivalent about competing with Google, despite budding robotic surgery rivalry. FierceMedicalDevices story | Follow @VarunSaxena2
> Startup Torax Medical has won FDA approval for its Fenix Continence Restoration System for fecal incontinence under a Humanitarian Device Exemption (HDE). More
> Spinal imaging informatics startup Ortho Kinematics nabbed $4 million in debt to back marketing of its VMA (Vertebral Motion Analysis) to assess spinal motion and instability. More
> Insulet ($PODD) has partnered with diabetes management startup Glooko to manage data for patients using its OmniPod System. More
Biotech News
@FierceBiotech: The scoop on every new drug approved in 2015. Feature | Follow @FierceBiotech
@JohnCFierce: Vtesse gets a BTD on Niemann Pick drug. Release | Follow @JohnCFierce
@DamianFierce: man with lots of money has no regrets about making more of it. More from Bloomberg | Follow @DamianFierce
> Accelerator's $48M biotech project looks to spark the NYC startup scene. Report
> Merck bets up to $595M on Quartet's chronic pain pipeline. News
> Biogen backs Rodin's Alzheimer's efforts in a $500M deal. Story
> Conatus pops on more incremental liver data for its lead drug. Article
Pharma News
@FiercePharma: Study finds some docs are not strongly recommending HPV vaccines for preteens. FierceVaccines story | Follow @FiercePharma
@EricPFierce: ICYMI: 18 months after the FDA slapped Cadila with a Form 483, it sends a warning letter. Article | Follow @EricPFierce
@CarlyHFierce: UPDATED: Former Valeant CFO Schiller to step in for hospitalized CEO Pearson. Report | Follow @CarlyHFierce
> Takeda snatches Baxalta plant to produce Entyvio in U.S. Story
> No M&A? No problem, Actelion says as it rolls out $160K-plus Uptravi. Article
> Rapid-fire pharma M&A could stall a bit in 2016: Bloomberg. More
Biotech Research News
> Cannabinoid drug reduces epileptic seizures in hard-to-treat children. Item
> CRISPR/Cas9 trifecta: Researchers correct genetic defect that triggers Duchenne muscular dystrophy. Report
> Mayo Clinic researchers tackle age-related stem cell dysfunction and metabolic disease. More
> Gut bacteria plays a big role in regulating impact of anti-inflammatory NSAIDs. Story
> UNC team spotlights Dicer as a new target for brain cancers. Article
Vaccines News
> Study finds some docs are not strongly recommending HPV vaccines for preteens. More
> Bavarian Nordic files for Nasdaq IPO. News
> Emergex to use Midatech nanoparticle tech for vaccines against infectious diseases. Story
> Norway's Bionor tests drug-vaccine combo against HIV. Item
> China approves Sinovac's vaccine for hand, foot and mouth disease. Article
Pharma Marketing News
> Actelion slaps $160K-plus price tag on new PAH med Uptravi. Item
> Native advertising for pharma: Winning format or slippery slope to regulatory headaches? Report
> Boosted by CV data, Lilly's Jardiance grabs market share from J&J, AZ. Story
> FDA sends fewer drug promotion action letters in 2015--but is that a good thing for pharma? More
> Novartis matches respiratory rivals with 'smart inhaler' collaboration. Article